We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.

We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.

Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.

Immutep is listed on the Australian Stock Exchange (IMM) and on the NASDAQ Global Market (IMMP) in the U.S. (ADR's).  

Media Releases

  • Oct 2018   05:38 PM
    TAKE NOTICE that the 2018 Annual General Meeting of shareholders of Immutep Limited (ACN 009 237 889) will be held at the time, date and place specified below: Time: 11.15am (AEDT) (registration co...read more
  • Oct 2018   05:17 PM
    CHAIRMAN'S LETTER I am pleased to present Immutep’s Annual Report for the 2018 financial year. This is my first Annual Report as your Chairman and our first Annual Report as Immutep Limit...read more
  • Immutep, Appendix 3B  (ASX:IMM)
    Oct 2018   03:59 PM
    New issue announcement, application for quotation of additional securities and agreement Ordinary Shares For further information please download PDF attached:
  • Immutep, Appendix 3B  (ASX:IMM)
    Oct 2018   05:33 PM
    New issue announcement, application for quotation of additional securities and agreement Ordinary Shares For further information please download PDF attached:
  • Immutep, Appendix 3Y  (ASX:IMM)
    Oct 2018   06:02 PM
    Change of Director's Interest Notice Mr Pete Meyers To view Notice please download PDF attached:
  • Oct 2018   05:55 PM
    New issue announcement, application for quotation of additional securities and agreement To view Notice please download PDF attached:
  • Oct 2018   03:28 PM
    SYDNEY, AUSTRALIA – October 2, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy tre...read more
  • Immutep, Appendix 3B  (ASX:IMM)
    Sep 2018   05:30 PM
    New issue announcement, application for quotation of additional securities and agreement Ordinary Shares For further information please download PDF attached:
  • Immutep, Appendix 3B  (ASX:IMM)
    Sep 2018   06:42 PM
    New issue announcement, application for quotation of additional securities and agreement Ordinary Shares For further information please download PDF attached:
  • Sep 2018   02:45 PM
    Form 604 National Nominees Ltd ACF Australian Ethical Investment Limited To view Notice please download PDF attached:

Latest Company News


Videos

Contact Information